Navigation Links
Helix BioPharma Corp. Announces Fiscal 2009 Results
Date:10/29/2009

Product revenue in fiscal 2009 totalled $3,244,000 and represents an increase of $292,000 or 9.9% when compared to product revenue in fiscal 2008 of $2,952,000. Product sales of Orthovisc® grew in fiscal 2009 while Klean-Prep(TM) revenue remained relatively stable. License fees and royalties in fiscal 2009 totalled $597,000 and represent a decrease of $42,000 or 6.6% when compared to fiscal 2008. The decrease reflects lower Klean-Prep(TM) royalty revenue from Helsinn-Birex which was offset by the final payment from Lumera Corporation of US$75,000 when it provided the Company with notice of termination of its sub-license agreement.

Cost of sales in fiscal 2009 and 2008 totalled $1,516,000 and $1,239,000, respectively. As a percentage of product revenues, cost of sales in fiscal 2009 and 2008 were 46.7% and 42.0%, respectively. In addition to some foreign exchange impact, cost of sales was also impacted by higher distribution costs. The increase in cost of sales, on a percentage, basis was mainly the result of lower average selling price per units sold of Orthovisc®. Lower pricing was offered on Orthovisc® to assist in customer retention for a scheduled launch of a new, single injection product in the first quarter of fiscal 2010.

Research and development expenditures in fiscal 2009 totalled $10,322,000 and represent an increase of $5,258,000 or 103.8% when compared to fiscal 2008. L-DOS47 and Topical Interferon Alpha-2b reflect an increase of 52.6% and 171.2%, respectively. The increase in research and development expenditures associated with L-DOS47, are primarily related to the scale-up manufacturing program and ongoing collaborative research initiatives in anticipation of furnishing product for future clinical testing. The increase in research and development expenditures associated with Topical Interferon Alpha-2b reflect the ongoing costs for the AGW Phase II clinical trial in Sweden and Germany in addition to scale-u
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
3. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
4. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
6. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
7. Laureate Pharma Announces Signing New Biopharmaceutical Development & Manufacturing Agreement
8. PDL BioPharma Completes October 1 Special Dividend Payment
9. DOR BioPharma Announces Private Equity Financing of $3.85 Million with its Partner Sigma-Tau and Other Institutional Investors
10. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
11. DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2014   Mast Therapeutics, Inc. (NYSE MKT: ... Edwin L. Parsley , D.O. has joined the Company ... Dr. Parsley has been actively engaged with ... February 2014.  He has served as Mast,s interim Chief ... Officer of Aires since April 2011.  Dr. Parsley previously ...
(Date:10/2/2014)... Oct. 1, 2014   Intarcia Therapeutics, Inc. ... four phase 3 clinical trials for ITCA 650 (exenatide, ... subcutaneous osmotic mini-pump). The first trial, FREEDOM-1, was a ... efficacy and safety of ITCA 650 in patients with ... 650 to be significantly superior to placebo for both ...
(Date:10/1/2014)... BOSTON , Oct. 1, 2014   ... market-leading provider of Anesthesia Information Management Systems (AIMS), ... Systems, LLC , a wholly owned subsidiary of ... healthcare information systems and connectivity solutions.  ... http://photos.prnewswire.com/prnh/20140930/149407 This partnership ...
Breaking Medicine Technology:Mast Therapeutics Announces Appointment Of Chief Medical Officer 2Mast Therapeutics Announces Appointment Of Chief Medical Officer 3Mast Therapeutics Announces Appointment Of Chief Medical Officer 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3
(Date:10/2/2014)... October 02, 2014 BamboofloorChina.com is a ... products have won great appreciation from the global customers ... working hard to make more excellent items. All its ... to help all clients. , The company has ... to its website. Furthermore, the company’s marketing specialist ...
(Date:10/2/2014)... Oct. 1, 2014 (HealthDay News) -- Children with autism ... they,re fully capable of being more active, a small ... levels of 29 children, some with autism and some ... day of moderate physical activity and 70 more minutes ... 17 children with autism scored lower on strength, but ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. ... of Columbia now have a total of 500 confirmed cases ... infecting children since the summer, U.S. health officials reported ... in recent weeks, but it,s not clear what role -- ... said. Health officials are also trying to determine if ...
(Date:10/1/2014)... A new research study published today in the ... in patients older than 50 years with moderate or ... benefit. , Researchers from the University of Melbourne randomly ... knee pain to no acupuncture or sham or pretend ... weeks with participants and acupuncturists blinded to laser and ...
(Date:10/1/2014)... research suggests the adage that encourages people to keep ... when it comes to exercise. When walking, staying focused ... to it appear shorter and help people walk there ... this technique to walking while looking around the environment ... of exercise. , "People are less interested in exercise ...
Breaking Medicine News(10 mins):Health News:High Quality Bamboo Panels Online At BamboofloorChina.com 2Health News:Kids With Autism Tend to Be Less Active, Study Says 2Health News:42 States Reporting Respiratory Virus That Targets Kids 2Health News:42 States Reporting Respiratory Virus That Targets Kids 3Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3
... and neck cancer that targets multiple peptides (parts of ... ,The researchers created the vaccine to ... mutated in most cancers and associated with poor clinical ... expresses unaltered, or "wild-type," p53 peptides in tumors. When ...
... critical genetic factor in the control of many aspects ... a genetic factor// , called a microRNA, in animal ... differentiation and development. ,MicroRNAS, or miRNAs, ... fine-tune levels of important proteins in cells. To learn ...
... was keenly interested in Buddhism and traveled to India in pursuit ... of 93. ,Born in 1913, Roaf spent his early ... the age of 13 and received a further scholarship in 1931 ... ,In 1934 Roaf's parents moved from London to Liverpool where he ...
... a universal problem. With a view to conserve water, ... the country.// ,In a press release the government ... India is about 1170 mm. However, there is very ... release further said that there had been considerable progress in ...
... Lebanon, a Mediterranean country, is considered notoriously image-conscious. It may ... militants// clashing fiercely all the time. ,But the ... ,Only that should explain why the Fist National Bank ... surgery. ,Its website dubs the 'plastic surgery loans' ...
... series of facts is one thing, understanding the big ... that// relational memory -- the ability to make logical ... is dependent on taking a break from studies and ... sleep. ,Led by researchers at Beth Israel ...
Cached Medicine News:Health News:Head and Neck Cancer Vaccine Targets Proteins to Create Immune Response 2Health News:Scientists Identify Critical Gene Factor in Heart Development 2Health News:Stress on Storage and Conservation of Rain Water by Govt of India 2Health News:Loans for Cosmetic Surgery in Lebanon 2Health News:To Understand the Big Picture, Give It Time -- and Sleep 2Health News:To Understand the Big Picture, Give It Time -- and Sleep 3
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Straight shafts. Overall length 3.9 inches....
Curved shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches....
Straight 6 mm platform. McPherson handle. Manufactured in titanium. Overall length 3.3 inches....
Curved shafts and tips with 6.5 mm tying platform. Flat serrated handle with dull finish. Overall length 3.9 inches. Overall length 3.9 inches....
Medicine Products: